CLINICAL TRIALS PROFILE FOR LITHIUM CITRATE
✉ Email this page to a colleague
All Clinical Trials for LITHIUM CITRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01892644 ↗ | Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | Terminated | Novartis | Phase 2 | 2013-05-01 | Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC. Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment. Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine. |
| NCT01892644 ↗ | Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | Terminated | Haukeland University Hospital | Phase 2 | 2013-05-01 | Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC. Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment. Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LITHIUM CITRATE
Condition Name
Clinical Trial Locations for LITHIUM CITRATE
Clinical Trial Progress for LITHIUM CITRATE
Clinical Trial Phase
Clinical Trial Sponsors for LITHIUM CITRATE
Sponsor Name
